Piramal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
February 08, 2023 at 10:34 am EST
Share
Piramal Pharma Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 17,159.7 million compared to INR 15,391.2 million a year ago. Revenue was INR 17,985.1 million compared to INR 16,996.8 million a year ago. Net loss was INR 901.8 million compared to net income of INR 1,633.7 million a year ago. Basic loss per share from continuing operations was INR 0.76 compared to basic earnings per share from continuing operations of INR 1.38 a year ago. Diluted loss per share from continuing operations was INR 0.76 compared to diluted earnings per share from continuing operations of INR 1.38 a year ago.
For the nine months, sales was INR 49,179.7 million compared to INR 44,277.4 million a year ago. Revenue was INR 51,185.8 million compared to INR 46,254 million a year ago. Net loss was INR 2,365.7 million compared to net income of INR 1,719 million a year ago. Basic loss per share from continuing operations was INR 1.99 compared to basic earnings per share from continuing operations of INR 1.46 a year ago. Diluted loss per share from continuing operations was INR 1.99 compared to diluted earnings per share from continuing operations of INR 1.46 a year ago.
Piramal Pharma Limited is an India-based pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. The Company has approximately 17 global facilities and a global distribution network in over 100 countries. The Company's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.
PIRAMAL PHARMA LIMITED 
